Scarica l'app Stockscreener
8.8824
1.77%
0.1424
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside - MSN
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - GlobeNewswire Inc.
Research Analysts Issue Forecasts for ORIC FY2024 Earnings - Defense World
Oric Pharmaceuticals Inc (ORIC-Q) QuotePress Release - The Globe and Mail
Wedbush Lowers Earnings Estimates for ORIC Pharmaceuticals - Defense World
(ORIC) Trading Advice - Stock Traders Daily
ORIC Pharmaceuticals (NASDAQ:ORIC) Earns “Outperform” Rating from Wedbush - Defense World
Oric Pharmaceuticals Reports Strong Financial Growth and Clinical Progress - TipRanks
Alkeon Capital Management LLC's Strategic Acquisition in ORIC Ph - GuruFocus.com
Creative Planning Invests $116,000 in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
FMR LLC Reduces Stake in ORIC Pharmaceuticals Inc - GuruFocus.com
ORIC Pharmaceuticals Inc Reports Q3 2024 Net Loss of $34.6 Milli - GuruFocus.com
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates - GlobeNewswire
ORIC Pharma Secures Major J&J, Bayer Partnerships; Reports $282M Cash Position | ORIC Stock News - StockTitan
ORIC Pharmaceuticals (NASDAQ:ORIC) Given “Buy” Rating at HC Wainwright - Defense World
ORICOric Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Long Term Trading Analysis for (ORIC) - Stock Traders Daily
Wells Fargo Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Overweight Recommendation - MSN
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $18.00 - Defense World
Dermavant acquisition expands Organon’s dermatology portfolio - Pharmaceutical Technology
ORIC-114 shows promise in preclinical cancer study By Investing.com - Investing.com Australia
ORIC-114 shows promise in preclinical cancer study - Investing.com
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - GlobeNewswire
Analytical Overview: ORIC Pharmaceuticals Inc (ORIC)’s Ratios Tell a Financial Story - The Dwinnex
ORIC Pharmaceuticals Inc (ORIC) shows promising results - US Post News
Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it’s Board of Directors - StockTitan
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance
SG Americas Securities LLC Takes $714,000 Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
The Manufacturers Life Insurance Company Buys 9,424 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Squarepoint Ops LLC Buys 16,613 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
(ORIC) Proactive Strategies - Stock Traders Daily
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times
ORIC® Pharmaceuticals Announces Presentation at the - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
XTX Topco Ltd Invests $153,000 in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Profund Advisors LLC Increases Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals Inc Inc. (ORIC) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
Trading Day Review: ORIC Pharmaceuticals Inc (ORIC) Loses Momentum, Closing at 10.00 - The Dwinnex
Cantor Fitzgerald Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Overweight Recommendation - MSN
ORIC Pharmaceuticals (NASDAQ:ORIC) Sees Large Volume Increase - Defense World
ORIC’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
Brokers Set Expectations for ORIC Pharmaceuticals, Inc.’s FY2024 Earnings (NASDAQ:ORIC) - Defense World
Rhumbline Advisers Has $655,000 Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals’ (ORIC) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Stocks of ORIC Pharmaceuticals Inc (ORIC) are poised to climb above their peers - SETE News
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Acquired by Victory Capital Management Inc. - Defense World
(ORIC) On The My Stocks Page - Stock Traders Daily
ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 11.6% - Defense World
ORIC Pharmaceuticals (ORIC) – Analysts’ Weekly Ratings Updates - Defense World
Bank of New York Mellon Corp Has $1.32 Million Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals stock holds Buy rating as analyst sees differentiation from competitor trials - Investing.com Canada
Nvidia, Apple Lead Thursday's Morning Market Cap Stock Movers - Investing.com
ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Buy Rating from HC Wainwright - Defense World
Quest Partners LLC Boosts Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Openbench, Inc. and Oric Pharmaceuticals, Inc. Launch Success-Driven Discovery Collaboration - Marketscreener.com
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):